EUVIMEDOpdag EUVIMED
Crossref

Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate‐specific antigen concentrations

Aleksander Ślusarczyk iD, Michael Baboudjian iD, Piotr Zapała, Takafumi Yanagisawa iD, Marcin Miszczyk, Marcin Chlosta, Paul Krumpoeck, Marco Moschini, Giorgio Gandaglia, Guillaume Ploussard iD, Juan G Rivas, Marcin Życzkowski and 5 more

The Prostate · 2023

DOI: 10.1002/pros.24609 ↗

At a glance

Journal article in The Prostate, 2023. Written by Aleksander Ślusarczyk and 16 co-authors. Institution: Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. Major MEDLINE topics: Prostate-Specific Antigen, Prostatic Neoplasms. Cited 3 times so far (Crossref); 22 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Patients with nonmetastatic prostate cancer (nmPCa) and high prostate‐specific antigen (PSA) levels due to the high likelihood of metastasis pose a clinical dilemma regarding their optimal treatment and long‐term outcomes after initial local therapy. We aimed to evaluate the oncologic outcomes of patients treated with radical prostatectomy (RP) or radiotherapy (RT) for nmPCa with high PSA levels.

Methods

We queried the Surveillance, Epidemiology, and End Results (SEER) database to identify patients diagnosed with nmPCa who received RP or RT from 2004 through 2015. We included nmPCa patients with high PSA levels categorized as ≥50 and ≥98 ng/mL, the highest level recorded in SEER. We used the Kaplan‐Meier method and Cox proportional hazards to analyze cancer‐specific (CSS) and overall survival (OS).

Results

We included 6177 patients with nmPCa and PSA ≥ 50 ng/mL at diagnosis; 1698 (27%) had PSA ≥ 98 ng/mL. Of these, 1658 (26.8%) underwent RP and 4519 (73.16%) patients received primary RT. Within a median of 113 months (interquartile range 74–150 months), the 5‐ and 10‐year CSS estimates were 92.3% and 81.5% respectively; 10‐year OS was 61%. In the PSA ≥ 98 ng/mL subgroup 5‐ and 10‐year CSS estimates were 89.2% and 76%, respectively. In multivariable analyses for CSS, ISUP grade group ( p < 0.001), N stage ( p < 0.001), treatment with RP (hazard ratio [HR] = 0.60, 95% confidence interval [CI] 0.43–0.83, p < 0.001), and patient's age ( p < 0.05) were associated with improved CSS. In the whole cohort of patients with PSA ≥ 50 ng/mL and RP subgroup, PSA failed to retain its independent prognostic value for CSS.

Conclusions

Patients treated with local therapy for nmPCa with very high PSA at diagnosis have relatively good long‐term oncological outcomes. Therefore, among well‐selected patients with nmPCa, high PSA levels alone should not preclude the use of radical local therapy. Potential selection bias limits inferences about the relative effectiveness of specific local therapies in this setting.

Subjects

MeSH terms (MEDLINE)

Prostate-Specific AntigenProstatic NeoplasmsMaleHumansPrognosisSalvage TherapyProstatectomyRetrospective Studies

Author keywords

high PSAnonmetastatic prostate cancerprostate-specific antigenradical prostatectomyradiotherapysurvival

Substances

Prostate-Specific Antigen

Authors and institutions

  • Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland.
  • Department of Urology, APHM, North Academic Hospital, Marseille, France.
  • Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
  • IIIrd Radiotherapy and Chemotherapy Department, Maria Skłodowska-Curie National Research Institute of Oncology, Warszawa, Poland.
  • Department of Urology, Jagiellonian University in Cracow, Kraków, Poland.

ORCID profiles: Aleksander Ślusarczyk, Michael Baboudjian, Takafumi Yanagisawa, Guillaume Ploussard, Paweł Rajwa

Cite

APA

Ślusarczyk, A., Baboudjian, M., Zapała, P., Yanagisawa, T., Miszczyk, M., Chlosta, M., Krumpoeck, P., Moschini, M., Gandaglia, G., Ploussard, G., Rivas, J. G., Życzkowski, M., Karakiewicz, P. I., Radziszewski, P., Leapman, M. S., Shariat, S. F., & Rajwa, P. (2023). Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate‐specific antigen concentrations. The Prostate. https://doi.org/10.1002/pros.24609

Vancouver

Ślusarczyk A, Baboudjian M, Zapała P, Yanagisawa T, Miszczyk M, Chlosta M, et al. Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate‐specific antigen concentrations. The Prostate. 2023. doi:10.1002/pros.24609

BibTeX
@article{lusarczyk2023,
  author = {Ślusarczyk, Aleksander and Baboudjian, Michael and Zapała, Piotr and Yanagisawa, Takafumi and Miszczyk, Marcin and Chlosta, Marcin and Krumpoeck, Paul and Moschini, Marco and Gandaglia, Giorgio and Ploussard, Guillaume and Rivas, Juan G and Życzkowski, Marcin and Karakiewicz, Pierre I and Radziszewski, Piotr and Leapman, Michael S and Shariat, Shahrokh F and Rajwa, Paweł},
  title = {Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate‐specific antigen concentrations},
  journal = {The Prostate},
  year = {2023},
  doi = {10.1002/pros.24609}
}
Start for free →